GPR109A receptor validation using knockout macrophages

Exploratory Score: 0.920 Price: $0.50 Mycoplasma pneumoniae pneumonia GPR109A knockout mouse macrophages Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting GPR109A, MAPK1, MAPK14, MAPK8, MAPK9 in GPR109A knockout mouse macrophages. Primary outcome: Differential MAPK pathway responses in GPR109A-/- cells

Description

GPR109A knockout mouse macrophages were used to confirm that the G-protein coupled receptor GPR109A mediates butyric acid's action in QTJD's therapeutic mechanism. This experiment was designed to validate the butyrate-GPR109A-MAPK pathway hypothesis. In GPR109A-/- macrophages, QTJD treatment still suppressed p38 and JNK1/2 MAPK proteins but showed no effect on ERK1/2, providing evidence that ERK1/2 inhibition by QTJD specifically requires GPR109A receptor signaling, while p38 and JNK1/2 inhibition may involve additional GPR109A-independent mechanisms. This experiment confirmed the involvement of the butyrate-GPR109A-MAPK pathway in QTJD's anti-inflammatory effects.

TARGET GENE
GPR109A, MAPK1, MAPK14, MAPK8, MAPK9
MODEL SYSTEM
GPR109A knockout mouse macrophages
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
Butyrate-GPR109A-MAPK signaling pathway
SOURCE
extracted_from_pmid_41754753
PRIMARY OUTCOME
Differential MAPK pathway responses in GPR109A-/- cells

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.920 composite

📖 Wiki Pages

mapk1-proteinproteinMAPK8 Protein (JNK1)proteinMAPK9 Protein (JNK2)proteinGPR109A (HCAR2) Agonists for NeurodegenerationtherapeuticMAPK8 GenegeneMAPK9 GenegeneMAPK1 GenegeneMAPK14 — Mitogen-Activated Protein Kinase 14 (p38αgeneMAPK1 Protein (ERK2)proteinMAPK14 ProteinproteinMAPK Signaling Inhibitors: Investment Landscape AninvestmentJNK1 (MAPK8)geneERK1 ProteinredirectMAPK/ERK Signaling Pathway in NeurodegenerationmechanismERK1 Proteinprotein

Protocol

Western blotting analysis of MAPK proteins in GPR109A knockout macrophages treated with QTJD

Expected Outcomes

GPR109A-dependent effects on ERK1/2 but not p38/JNK1/2

Success Criteria

Selective loss of ERK1/2 inhibition in GPR109A-/- cells

Related Hypotheses (1)

Targeted Butyrate Supplementation for Microglial Phenotype Modulation0.700

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.